Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

EPT Disclosure- Amendment

9 Apr 2010 11:33

RNS Number : 9602J
Credit Suisse Securities (Eur) Ltd
09 April 2010
 

FORM 38.5 (a)

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS

WITH RECOGNISED INTERMEDIARY STATUS

DEALING IN A CLIENT-SERVING CAPACITY

(Rule 38.5(a) of the Takeover Code)

AMENDMENT

 

The amendment in position represents the effect of a late booked trade, book transfer and/or cancel/correct activity

 

1. KEY INFORMATION

Name of exempt principal trader

Credit Suisse Securities (Europe) Limited

Company dealt in

Ark Therapeutics Group PLC

Class of relevant security to which the dealings being disclosed relate (Note 1)

Ordinary Shares

Date of dealing

07-Apr-2010

2. DEALINGS (Note 2)

(a) Purchases and sales

Total number of securities purchased

Highest price paid (Note 3)

Lowest price paid (Note 3)

26766

0.0975 (GBP)

0.0975 (GBP)

 

Total number of securities sold

Highest price received (Note 3)

Lowest price received (Note 3)

29548

0.0975 (GBP)

0.0975 (GBP)

(b) Derivatives transactions (other than options)

Product name, e.g. CFD

Long/short (Note 4)

Number of securities (Note 5)

Price per unit (Note 3)

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Product name,e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 5)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 3)

(ii) Exercising

Product name, e.g. call option

Number of securities

Exercise price per unit (Note 3)

3. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

Date of disclosure

09-Apr-2010

Contact name

Collins, Carolyn/Simon Crawley

Telephone number

0207 888 0241

Name of offeree/offeror with which connected

Ark Therapeutics Group PLC

Nature of connection (Note 6)

ADVISOR

Notes The Notes on Form 38.5(a) can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
EMMLLFVISLIAIII
Date   Source Headline
19th May 20087:00 amRNSResearch Update
16th May 20087:00 amRNSInterim Management Statement
24th Apr 20084:57 pmRNSAGM Results
22nd Apr 20087:00 amRNSRegulatory Update
17th Apr 20087:00 amRNSProduct Update
1st Apr 20083:26 pmRNSAnnual Information Update
31st Mar 200812:39 pmRNSTotal Voting Rights
28th Mar 20081:46 pmRNSRe Appointment
20th Mar 20087:00 amRNSBoard Appointment
11th Mar 20087:01 amRNSLaunch of Neuropad
11th Mar 20087:01 amRNSFinal Results
5th Mar 20085:20 pmRNSHolding(s) in Company
13th Feb 20087:00 amRNSManufacturing Update
31st Jan 200810:27 amRNSVoting Rights and Capital
23rd Jan 20084:56 pmRNSNotice of Results
18th Jan 20087:01 amRNSResearch Update
17th Jan 200810:42 amRNSRe: Employee Benefit Trust
11th Jan 200810:33 amRNSDirector/PDMR Shareholding
9th Jan 20084:50 pmRNSResignation of NED
8th Jan 20087:00 amRNSAcquisition
19th Dec 20074:37 pmRNSPrice Monitoring Extension
6th Dec 20075:48 pmRNSHolding(s) in Company
5th Dec 20071:39 pmRNSHolding(s) in Company
5th Dec 200712:41 pmRNSHolding(s) in Company
4th Dec 20075:40 pmRNSBlocklisting Interim Review
4th Dec 20074:56 pmRNSBlocklisting Interim Review
4th Dec 200711:50 amRNSHolding(s) in Company
30th Nov 200712:35 pmRNSDirector/PDMR Shareholding
30th Nov 200712:10 pmRNSVoting Rights and Capital
29th Nov 20072:17 pmRNSResult of EGM
28th Nov 20074:27 pmRNSRe: Placing and Open Offer
6th Nov 20077:01 amRNSPlacing and Open Offer
30th Oct 20075:08 pmRNSHolding(s) in Company
25th Oct 20077:01 amRNSResearch Update
22nd Oct 20071:01 pmRNSHolding(s) in Company
16th Oct 20073:23 pmRNSHolding(s) in Company
10th Oct 20077:01 amRNSRe Agreement
8th Oct 20077:00 amRNSRe Agreement
28th Sep 20073:06 pmRNSVoting Rights and Capital
31st Aug 200710:39 amRNSVoting Rights and Capital
29th Aug 20077:01 amRNSInterim Results
20th Aug 20077:02 amRNSRe: Product Launch
31st Jul 200711:23 amRNSVoting Rights and Capital
26th Jul 20077:01 amRNSResearch Update
24th Jul 200711:18 amRNSNotice of Results
23rd Jul 20077:01 amRNSRe: Cerepro
6th Jul 20077:00 amRNSEPO Grant Stroke Patent
29th Jun 20071:14 pmRNSVoting Rights and Capital
22nd Jun 20074:03 pmRNSHolding(s) in Company
15th Jun 20072:45 pmRNSDirector's Share Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.